top of page


New: Download the ISTH 2022 App here. This app is essential for navigating the ISTH 2022 Congress in person. There will not be a large printed program book, so use this tool to access session information on the go. 


The ISTH 2022 Congress Program will feature:

  • 4 plenaries 

  • 28 total State-of-the-Art sessions

  • 80 total oral communication sessions each featuring four presentations on the latest abstracts.

  • 24 Scientific and Standardization Committee (SSC) subcommittee sessions

  • 30 master classes and 12 career development sessions

  • Trainee Session

  • Early career programs

  • Nurses Forum sessions 

  • Poster sessions

  • Supported symposia and presentation theaters 

  • Engaging industry exhibition: See exhibitors and floor plan here.


The ISTH 2022 Congress will feature four plenary sessions with these world-renowned speakers:

Steffen Massberg Circle.png

Steffen Massberg

Gus Born
Memorial Lecture

July 9 | 17:00-17:30
Thrombosis and the Innate Immune Cell Axis: From Bacteria to Virus

Rob Medcalf Circle.png

Robert Medcalf

Rosemary Biggs
Memorial Lecture

July 10 | 09:30-10:15
Fibrinolysis, Immunity and the Injured Brain


Anne Godier Circle.png

Anne Godier
M.D., Ph.D.

Katharine Dormandy
Memorial Lecture

July 11 | 9:30-10:15
Personalized Management of Acquired Bleeding Disorders

Sarah Teichmann Circle.png

Sarah Teichmann

David Weatherall
Memorial Lecture

July 12 | 9:30-10:15
The Human Cell Atlas: Blood and Vasculature


About the memorial lecture honorees:

  • Gus Born (1921-2018) fled Germany in 1933 and settled in the UK, with his family, headed by his father Max Born, who in 1954 won the Nobel Prize for Physics for his “fundamental research in quantum mechanics”. As a doctor serving with the Royal Army Medical corps, Gus Born was one of the first to witness the after-effects of the atomic bomb at Hiroshima. He was struck by the severe bleeding disorders seen in the survivors, which was due to lack of platelets due to radiation damage. This drove much of his later research.  He invented the light transmission aggregometer in the 1960s, transforming platelet function testing and still a key investigation for platelet function today. He did not patent the device, saying that scientific advances with medical implications should not be exploited for commercial gain.

  • Rosemary Biggs (1912-2001) was a pioneering Haematologist based in Oxford. In 1952, she devised a new test, the thromboplastin generation test for detecting Haemophilia. The same year with Robert MacFarlane, she discovered factor IX that they originally names Christmas factor, after Stephen Christmas the first patient to be deficient in Factor IX. These discoveries contributed to the development of the cascade model of coagulation. In 1953, Biggs & MacFarlane wrote the first UK guidelines for treating Haemophilia. Their proposal for a national haemophilia centre that housed departments for treatment, research and blood plasma fractionation was approved in 1964. At that time three–quarters of those known to have Haemophilia were treated at Oxford. She directed the Oxford Haemophilia centre until her retirement in 1977.

  • Katharine Dormandy (1926-1978) established the haemophilia service at the Royal Free Hospital in London and was known for advocating for the care of haemophiliacs. The service originally ran out of a caravan parked outside the hospital that had been donated by the Haemophilia Society. By 1970, the Haemophilia Centre expanded to utilize the veranda of an existing ward; although the caravan was still utilized. In recognition of all of her work, in 1978 a dedicated building for the care of Haemophilia was built at the Royal Free hospital, and was named the Katherine Dormandy Haemophilia Centre.

  • David Weatherall (1921-2018) graduated from medical school in 1956. After house training he joined the Army for 2 years and was stationed in Singapore. There he treated the daughter of a Gurkha soldier with thalassemia, which sparked a lifelong interest in this disease. He used car batteries and filter paper for electrophoresis while he was there. Eventually he became Professor of Haematology in Liverpool and then Nuffield Professor of Clinical Medicine in Oxford where he led pioneering research into molecular genetics of the hemoglobinopathies and was a leading expert on the thalassaemias. While he was not a full time “clotter” his work paved the way for molecular work in thrombosis & haemostasis. In 2002, he wrote a major report on the application of genomics for global health for the World Health Organisation.

bottom of page